Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252411 | 0.81 | FFAR1 (0.65) | MAPTALDH1A1KMT2AGAAMMP2 | |
| SCHEMBL10971280 | 0.79 | PARP15 (0.56) | MAPTALDH1A1KMT2AGAACA1 | |
| SCHEMBL3372818 | 0.79 | MAPT (0.62) | MAPTALDH1A1KMT2AGAAMMP2 | |
| SCHEMBL15647515 | 0.79 | MAPT (0.53) | MAPTALDH1A1KMT2AGAAMMP2 | |
| SCHEMBL2346349 | 0.79 | FFAR1 (0.62) | MAPTALDH1A1KMT2AGAAMMP2 | |
| SCHEMBL10971279 | 0.79 | MAPT (0.53) | MAPTALDH1A1KMT2AGAAMMP2 | |
| Lithium Ion SCHEMBL11882137 | 0.77 | ATF4 (0.51) | MAPTALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL2163526 | 0.76 | L3MBTL1 (0.57) | MAPTALDH1A1KMT2AGAAMMP2 | |
| SCHEMBL4114747 | 0.76 | RAB9A (0.55) | MAPTALDH1A1KMT2AGAAMMP2 | |
| SCHEMBL4284626 | 0.76 | MMP2 (0.71) | MAPTMMP2KDM4EMMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1568688-B1 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT | MOCHIDA PHARM CO LTD (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-7494987-B2 | Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20060040985-A1 | Therapeutic agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1568688-A1 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040985-A1 | Therapeutic agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient | BRD7, RBBP7, NR0B1 | MAPT 4685/4885ALDH1A1 1424/4885KMT2A 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.